What Partex Global Gmbh does

Partex Global Gmbh, doing business as Partex.AI, is a Germany-incorporated AI-native drug-discovery company that operates an integrated therapeutic asset accelerator spanning four business units: Therapeutics, Exchange, Labs, and Real-World Data. The Therapeutics unit identifies and advances drug candidates; Exchange provides a marketplace for licensing or co-developing AI-discovered assets; Labs operates wet-lab facilities to experimentally validate AI-generated hypotheses; and Real-World Data aggregates holistic patient and clinical datasets from healthcare providers, insurers, and research institutions to feed back into the platform. The company is currently incubating three oncology drug candidates through dedicated Special Purpose Vehicles (SPVs), enabling equity-linked returns rather than purely upfront licensing economics.

Name

Partex Global Gmbh

Legal name

Partex Global Gmbh

Website

https://partex.ai

Company type

Private

Operating status

Operating

Short description

Partex Global Gmbh (Partex.AI) is an AI-native therapeutic asset accelerator that uses a proprietary foundation model, wet-lab validation, and real-world data to discover, incubate, and license oncology drug assets for pharmaceutical and biotech partners.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Agents & Autonomous Workflows (Tool Use, Planning, Multi-Agent) (HDAAACAF)

akta.pro secondary industry

End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA)

Keywords

• AI drug discovery
• Therapeutic asset optimization
• Pharmaceutical licensing services
• Drug pipeline analytics
• Biotech data platforms

Headquarters

HQ city

Eschborn

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Therapeutics (SPV Model): Incubating drug assets in oncology within focused Special Purpose Vehicles (SPVs). Partex.AI identifies late stage preclinical to early clinical drug assets with strong scientific foundations but suboptimal development paths, optimizing them towards key value inflection points. Revenue is generated through asset development and eventual licensing or sale.
2. Exchange (Licensing Services): Partnering with pharma and biotech companies to unlock value from deprioritized or off-strategy drug assets through AI-driven in- and out-licensing. Facilitates and accelerates pipeline optimization through value-based collaboration models. Revenue derived from licensing facilitation fees and success-based arrangements.
3. Labs Services: Developing next-generation functional assays and high-throughput experimental screening to test and confirm AI-driven predictions. Provides experimental validation services supporting AI hypotheses for partners.
4. Real-World Data Partnerships: Building scalable global partnerships with healthcare providers to leverage RWD for drug development and treatment optimization. Generates revenue through data licensing and collaborative research arrangements.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Partex.AI is an AI-powered therapeutic asset accelerator that uses proprietary AI models, unrivalled computing power, and holistic datasets to evaluate and optimize late-stage preclinical to early clinical drug assets for pharmaceutical and biotech partners. It operates four interconnected business units — Therapeutics (asset incubation in oncology SPVs), Exchange (AI-driven in- and out-licensing), Labs (functional assays and high-throughput screening), and Real-World Data (global healthcare data partnerships).

Product overview

Partex.AI operates as a unified platform with four interconnected business units: Therapeutics (incubating oncology drug assets), Exchange (AI-driven licensing marketplace), Labs (experimental validation of AI predictions), and Real-World Data (global healthcare data partnerships). The platform uses proprietary AI models and computing power to optimize therapeutic assets across the drug development lifecycle.

Differentiator

Problem solved

Functional benefit

Brands

• Therapeutics: Identifying late stage preclinical - early clinical drug assets with strong scientific foundations but suboptimal development paths, Partex.AI's proprietary models optimize therapeutics towards their key value inflection. Currently incubating three promising drug assets in oncology within focused SPVs.
• Exchange
• Labs
• Real-World Data

Products and services

• Therapeutics AI-driven identification and incubation of late-stage preclinical to early clinical drug assets with strong scientific foundations but suboptimal development paths, optimized toward key value inflection points. Currently incubating three oncology drug assets within focused Special Purpose Vehicles (SPVs) for pharmaceutical and biotech partners.
• Exchange AI-driven in- and out-licensing platform that helps pharmaceutical and biotech partners unlock value from deprioritized or off-strategy drug assets through data-enabled asset evaluation and repositioning, with adaptable value-based collaboration models.
• Labs Next-generation functional assays and high-throughput experimental screening services that rigorously test and confirm AI-driven predictions, integrating advanced computational modeling with hands-on laboratory science in disease-relevant systems to deliver a closed-loop AI validation model.
• Real-World Data Scalable global partnership program with healthcare providers to leverage Real-World Data for drug development and treatment optimization, supporting equitable and trustworthy data collaborations that improve patient outcomes.
• Partex.AI Platform Unified AI-powered therapeutic asset accelerator platform combining unrivalled computing power, proprietary AI models, multidisciplinary expertise, and holistic datasets to develop drugs faster, more cost effectively, and more targeted than traditional pipelines.

Quantifiable outcome

• Reduction in drug licensing timeline from 3+ years to shorter cycles through AI-driven evaluation and optimization
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Exscientia: AI-native pharma company using end-to-end AI platforms to design and develop therapeutics, with both owned pipeline and pharma partnerships. Direct competitor in the AI-driven asset acceleration space Partex.AI occupies.
• BenevolentAI: AI-driven drug discovery company combining biomedical knowledge graphs with ML to identify and prioritize therapeutic assets. Comparable to Partex.AI's Exchange/asset-evaluation business, with published pharma collaborations.
• XtalPi: AI-driven drug discovery company combining quantum physics, AI, and large-scale wet-lab robotics. Comparable to Partex.AI's integrated AI+wet-lab approach and asset acceleration positioning, with deep pharma partnerships in Asia and globally.
• Atomwise: AI-based small molecule drug design company using proprietary models and partnerships with pharma and agrochemical companies. Comparable to Partex.AI's platform technology and pharma partnership model, with established in-licensing style collaborations.
• Schrödinger: Computational drug discovery platform combining physics-based simulation with AI/ML for asset evaluation and optimization. Closely comparable to Partex.AI's Exchange and Therapeutics offerings, with established pharma partnerships and a public-market valuation benchmark.
• Recursion Pharmaceuticals: Publicly listed AI-driven drug discovery company combining high-throughput wet-lab experimentation with proprietary foundation models. Directly comparable to Partex.AI's closed-loop AI+wet-lab model and asset-acceleration thesis, though operating at significantly larger scale.
• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate therapeutic development. Comparable to Partex.AI in combining proprietary data generation with ML models and pharma partnerships, with backing from top-tier VCs.

Emerging players

• Isomorphic Labs: Alphabet-backed AI drug discovery spin-out leveraging DeepMind's foundation models for therapeutic asset design. Comparable to Partex.AI's foundation-model-driven approach with deeper capital backing and pharma partnerships with Novartis and Eli Lilly.
• Owkin: AI biotech combining federated learning on healthcare data with pharma partnerships to accelerate drug development. Comparable to Partex.AI's Real-World Data business unit and AI-for-pharma positioning, though focused on oncology immunology.

Broad incumbents

• Tempus AI: Publicly listed AI-driven precision medicine company combining multimodal data, AI models, and clinical workflow tools for pharma and providers. Comparable to Partex.AI's RWD and AI-platform thesis, with broader scope and established pharma enterprise sales.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Partex Global Gmbh